Project Grant R41HL172481
Award Date
9/17/24
Completion Date
9/16/25
Dollars Obligated
$300K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Acepre, LLC (NX6XWKC8C4B5)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Columbia, SC 29209, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $114,938 to Brigham & Women's Hospital Inc. to investigate novel epigenetic mechanisms underlying calcific aortic valve disease (CAVD). The research aims to define the histone code of CAVD, determine downstream translational and post-translational signaling targets, and examine the role of epigenomic modifications on...
This Project Grant award of $116,250 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research at The Johns Hopkins University to study the prevalence, risk factors, and progression of calcific aortic valve disease (CAVD) and severe aortic stenosis in persons over 75 years old. The research aims to: 1) identify long-term risk factors for the development of aortic valve calcification, 2) create population percentiles for aortic valve...
This $147,486 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanistic relationship between bicuspid aortic valve (BAV)-induced mechanical stress and the development of premature calcific aortic stenosis. The research project, conducted by the Medical College of Wisconsin, Inc., aims to: 1) Delineate the BAV-specific mechanosensitive signaling pathway between vascular endothelial cells...
This $304,119 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of innovative in vitro 3D atherosclerosis models and high-throughput drug screening assays by Endomimetics LLC. The key objectives are to create an automated, precise approach for fabricating advanced 3D vascular sheet and atherosclerosis models, which will enable efficient, high-throughput testing of drug...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
The National Heart Lung and Blood Institute (NHLBI) awarded a $810,650 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cedars-Sinai Medical Center. The funding will support the development and validation of an artificial intelligence (AI)-enabled algorithm to characterize fibrotic and calcific aortic valve tissue from computed tomography angiography (CTA) scans. The goal is to predict rapid aortic valve disease progression and create an AI-powered risk score to predict...
This $750,345 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Pittsburgh. The funding supports research to investigate the role of telomerase reverse transcriptase (TERT) in the osteogenic reprogramming of aortic valve interstitial cells, which can lead to calcific aortic valve disease. The project aims to elucidate the epigenetic and transcriptional changes directed by...
This $299,790 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel allosteric modulators of the thrombin receptor, protease-activated receptor 1 (PAR1), called Parmodulins, for the treatment of sickle cell disease (SCD). The project aims to identify optimized Parmodulins with improved potency and oral activity, and confirm their efficacy in mouse models of SCD, including...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $413,595 Project Grant to Unandup, LLC, a medical technology firm based in St. Louis, Missouri. The grant will fund the development of a magnetic rotational atherectomy platform to debulk severely calcified coronary lesions and improve percutaneous coronary intervention procedures. Key innovations include the use of magnetic fields to control the atherectomy...
This Project Grant award, valued at $402,911.00, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to develop a method for generating a large number of therapeutic nanovesicles (NVs) from mesenchymal stem cells (MSCs) using an extrusion process. These engineered "cell-drones" will be tested for their ability to promote tissue repair in mouse and porcine models of cardiac...